OptiNose, Inc. announced preliminary XHANCE net product revenue results for the first quarter ended March 31, 2024. for the quarter, the company reported preliminary XHANCE net product revenue of $14.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -0.95% | +0.97% | -19.38% |
Jun. 27 | Optinose Announces Expanded Access to XHANCE with Addition to National Commercial Formularies | CI |
May. 20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.38% | 151M | |
+55.55% | 816B | |
+39.42% | 634B | |
-6.83% | 351B | |
+17.15% | 323B | |
+7.09% | 293B | |
+14.21% | 238B | |
+1.23% | 222B | |
+13.80% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024